2891 results about "Polyclonal antibodies" patented technology

A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.

The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed. The use of divinyl sulfone (DVS) as the linker arm molecule for forming rapamycin-protein conjugate immunogens is described. DVS-linked rapamycin-protein conjugates were found to elicit antibodies with greater specificity to the rapamycin molecule than succinate linked conjugates.

Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful V_H and V_L pairs useful when preparing the polyclonal antibody.

The invention discloses a fluorescent microsphere immunity-chromatography test strip for detecting food-borne pathogenic microorganisms in a rapid, specific, qualitative and quantitative manner and a preparation method thereof. Filter paper, a sample pad, a glass fiber membrane spray-painted by fluorescent microsphere marked food-borne pathogenic microorganism monoclonal antibodies or polyclonal antibodies, a nitrocellulose membrane and drinking paper are stuck to an underplate orderly in a related joint manner; the food-borne pathogenic microorganism monoclonal antibodies or the polyclonal antibodies are coated on the nitrocellulose membrane and are used as a detection area; and anti-mouse antibodies are coated on the nitrocellulose membrane and used as a quality control area. The test strip has the preparation steps as follows: (1) samples to be detected are processed; (2) the nitrocellulose membrane is prepared; (3) a fluorescent microsphere pad is prepared; (4) the test strip is assembled; and during the detection process, the CCD scanning technique is utilized to collect all emission spectrums, and then the emission spectrums are analyzed through a fluorescence analyzer and relevant software after accumulation and multiplication, so that the quantitative detection is realized. The fluorescent microsphere immunity-chromatography test strip and the preparation method thereof are mainly used for qualitative and quantitative detection of all the food-borne pathogenic microorganisms in food safety inspection.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

The invention provides a human mycoplasma pneumoniae gold-marked silver-stained immunochromatographic assay kit and a preparation method and application thereof. The assay kit comprises a detection card and a silver-stained sensitivity-enhanced pad, wherein the detection card is composed of a bottom plate, a sample pad, an absorbent pad, a conjugate pad and a detection layer; the conjugate pad is coated with a colloidal gold-marked polyclonal antibody mixture of colloidal gold marked rabbit anti-human mycoplasma pneumoniae P1 protein and P30 protein; the detection layer is composed of a solid phase nitrocellulose membrane with a detection line and a quality control line; the detection layer is bonded on the bottom plate, the conjugate pad and the absorbent pad are partially overlapped with the detection layer respectively and are bonded with the detection layer and the bottom plate respectively; the sample pad and the conjugate pad are partially overlapped to be bonded with the conjugate pad and the bottom plate respectively; and the silver-stained sensitivity-enhanced pad consists of a AgNO3 pad and a restoring pad. The human mycoplasma pneumoniae gold-marked silver-stained immunochromatographic assay kit can effectively improve the detection sensitivity of the human mycoplasma pneumoniae, has the strong specificity and has the high application value in the aspects of clinical diagnosis of human mycoplasma pneumoniae, etiology identification, epidemiological investigation and the like.

The invention discloses a coronavirus rapid detection kit based on S protein ligand and ACE2 receptor competitive chromatography. The coronavirus rapid detection kit comprises quantum dot labeled ACE2protein, quantum dot labeled rabbit IgG, recombinant coronavirus spinous process protein S1, goat anti-rabbit IgG polyclonal antibody, an immunochromatographic test strip and other materials. The detection sensitivity is improved through quantum dot fluorescence labeling and multistage coupling amplification signals, the detection specificity is improved and the antibody research and developmentcycle is avoided by utilizing the ligand and receptor binding principle, the kit capable of rapidly detecting coronavirus is provided, and the biosafety in the detection process is guaranteed by establishing a virus inactivation system. The kit disclosed by the invention is suitable for detecting various biological samples and environmental samples such as oral mucosa liquid, respiratory tracts, whole blood, plasma, serum, excrement and the like, and can be applied to rapid detection of coronaviruses taking ACE2 as a receptor, such as SARS-CoV-19, SARS-CoV, HCoV-NL63 and the like.

The invention relates to a kit for determination of human alpha-fetoprotein content by a latex-enhanced immunoturbidimetry. The kit provided by the invention comprises an alpha-fetoprotein R1 reagent, an alpha-fetoprotein R2 reagent and an alpha-fetoprotein calibrator, wherein the alpha-fetoprotein R1 reagent comprises one or more electrolytes, a coagulation accelerator, one or more stabilizing agents, one or more surfactants, an antiseptic and a buffer solution; the alpha-fetoprotein R2 reagent comprises latex particles coated by polyclonal antibodies capable of resisting a human alpha-fetoprotein, one or more electrolytes, one or more stabilizing agents, one or more surfactants, an antiseptic and a buffer solution; and the alpha-fetoprotein calibrator comprises an antiseptic, one or more electrolytes, one or more stabilizing agents, alpha-fetoprotein antigens and a buffer solution. The kit has strong specificity and high sensitivity, is homogeneous and stable, can be used fast and conveniently and can be used for various biochemical analyzers.

The invention relates to a magnetic corpuscule chemiluminescent enzyme immunoassay kit for detecting carbohydrate antigen and the application method thereof. The kit comprises FITC antibody-coated magnetic corpuscules; a marker solution prepared by mixing the FITC-marked carbohydrate antigen monoclonal antibody and the enzyme-marked carbohydrate antigen monoclonal antibody; a carbohydrate antigen standard sample solution; a concentrated washing solution; and a luminescent substrate solution, wherein carbohydrate antigen optionally adopts one of CA72-4, CA50, CA19-9, CA242, CA15-3, CA27-29 and CA125. The enzyme-marked antibody and the FITC-marked antibody are the monoclonal antibodies corresponding to the antigens. The FITC antibody coating the magnetic corpuscules adopts a polyclonal antibody or a monoclonal antibody. The marker solution is prepared by mixing an FITC-marked capture antibody working solution and an enzyme-marked antibody pair working solution by the volume ratio of 1:(1-3). Compared with the known kit for mensurating the carbohydrate antigen, the kit has the advantages of high flux, high sensitivity, wide linear range, rapidness, etc., and has a wide application prospect for the clinical inspection, etc.

This invention related generally to methods of detecting and quantifying biomarkers of oxidative stress in proteins. The biomarker may be any amino acid that has undergone oxidation (or other modification, e.g. chloro-tyrosine, dityrosine). Emphasis is given herein on oxidized sulfur- or selenium-containing amino acids (SSAA). The biomarker of oxidative stress in proteins may be detected with an antibody that binds to oxidized amino acids, specifically oxidized sulfur- or selenium-containing amino acids. The antibody may be monoclonal or polyclonal. The presence of biomarker or amount of biomarker present in a sample may be used to aid in assessing the efficacy of environmental, nutritional and therapeutic interventions, among other uses.

The present invention belongs to the field of biological detection. Multi-line immunochromatographic test strip for semi-quantitative detection of aflatoxin B₁ comprises a paperboard, wherein a water-absorbing pad, a detection pad, a gold-labeled pad and a sample pad are adhered sequentially on one surface of the paperboard from top to bottom, wherein each adjacent pads is overlapped and connected, the detection pad uses a nitrocellulose film as a backing pad, the nitrocellulose film is provided with a transverse control line, a test line I, a test line II and a test line III, wherein the control line is coated with a rabbit anti-mouse polyclonal antibody, and the test line I, test line II and test line III are coated with aflatoxin B₁-bovine serum albumin conjugate (AFB₁-BSA), respectively: and the gold-labeled pad is transversely coated with a nanogold-labeled anti-aflatoxin B₁ monoclonal antibody. Said test strip is used for semi-quantitative detection of aflatoxin B₁, and is characterized by quick detection, simple procedure and high sensitivity.

A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.

The invention discloses immunofluorescence chromatography test paper for CRP (C-reaction protein)/SAA (Serum amyloid A protein) quantitative combined detection, aiming at providing a test strip capable of realizing quantitative combined detection on the content of CRP/SAA in human peripheral blood and quantitative combined detection on the content of CRP/SAA in venous blood. The immunofluorescence chromatography test paper is technically characterized by comprising a box with a cover, wherein a detection test strip and a blood diluent bottle are arranged in the box, the detection test strip comprises a bottom lining, the bottom lining is provided with a nitrocellulose membrane, one end of the nitrocellulose membrane is connected with a fluorescent microsphere marked antibody fixation pad, the fluorescent microsphere marked antibody fixation pad is connected with a sample pad, the other end of the nitrocellulose membrane is connected with an absorption pad, the fluorescent microsphere marked antibody fixation pad is coated by a CRP monoclonal antibody and an SAA monoclonal antibody, a CRP detection line coated by a CRP monoclonal antibody, an SAA detection line coated by an SAA monoclonal antibody, and a quality control line coated by a goat-anti-mouse IgG polyclonal antibody are arranged on the nitrocellulose membrane in parallel. The immunofluorescence chromatography test paper belongs to the technical field of biological medicines.

Nucleic acid sequences coding for the chondroitinase ABC gene and isolated chondroitinase ABE protein produced in a host cell transformed with a nucleic acid vector directing the expression of a nucleotide sequence coding for chondroitinase ABE protein described. Chondroitinase ABC prepared by chemical synthesis also described. Monoclonal and polyclonal antibodies which are specifically reactive with chondroitinase ABC protein are disclosed. The isolated chondroitinase ABC can be used in methods of treating intervertebral disc replacement, promoting neurite regeneration, and detecting galactosaminoglycans.

The invention relates to a high-sensitivity trace of protein measuring method based on bead and nm metal probe, comprising: labelling the bead using monoclonal antibody of protein to measure; labelling the polyclonal antibody of protein to measure on nm metal probe and at the same time labelling a DNA probe with biotin label on the nm metal probe; labelling horseradish peroxidase on the DNA probe of nm metal probe by biotin-streptavidin reaction to form nm metal probe; mixing the labelled bead and nm metal probe and protein sample and incubating for a period of time at 37 degree; and then washing the nm metal probes which do not react; developing using TMB development system, therefore the protein can be quantificationally detected. The detection time can be reduced to 1-1.5 hours and the sensitivity can be pg/ml.

The invention relates to an aflatoxin B1 flow lag immunization time distinguishing fluorescence rapid-detection kit and an application thereof. The kit comprises a fluorescent test strip and a sample reaction bottle containing an europium-labeled anti-aflatoxin B1 monoclonal antibody lyophilized product, wherein the fluorescent test strip comprises a cardboard, a water absorption pad, a detection pad and a sample pad are sequentially pasted on one surface of the cardboard from top to bottom, adjacent pads are connected at the connection in an overlapping manner, the detection pad treats a cellulose nitrate membrane as a base pad, a transverse quality control line and a detection line are arranged on the cellulose nitrate membrane from top to bottom, the quality control line is coated with a rabbit anti-mouse polyclonal antibody, and the detection line is coated with an aflatoxin B1 bovine serum albumin conjugate; and the anti-aflatoxin B1 monoclonal antibody is secreted by a hybridoma cell strain having a preservation number of CCTCC NO.C201015. The kit can be used for the quantitative determination of the content of the aflatoxin B1, and has the advantages of simple operation, rapidness and high accuracy.

The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immonoglobulin products.